Discover trends, market shifts, and competitive outlooks for the malignant mesothelioma industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Malignant Mesothelioma Market Size Shifted, And What Is the Outlook Through 2034?

In recent years, the market size for malignant mesothelioma has seen significant growth. It is projected to expand from $2.46 billion in 2024 to $2.63 billion in 2025 with a compound annual growth rate (CAGR) of 6.8%. The historically robust growth can be tied to factors such as increased funding in oncology research, a surge in legal cases related to asbestos, a rise in investments in hospitals, an increase in the elderly population, and the expansion of ai-driven platforms for drug discovery.

The market size for malignant mesothelioma is projected to experience significant expansion in thecoming years. The expectation is that it will reach $3.41 billion by 2029, increasing at a compound annual growth rate (CAGR) of 6.7%. This growth during the forecasted period can be traced back to the rising acceptance of immunotherapy treatments, an amplified focus on personalized medicine, an upward trend in the use of minimally invasive surgical procedures, escalated healthcare spending, and an increase in clinical trials. Key trends during this period include progress in the areas of immunotherapy and personalized medicine, initiatives for early detection, advancements in minimally invasive surgical methods, and regulatory endorsements.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22046&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Malignant Mesothelioma Market?

Escalating efforts in clinical research and development are forecasted to drive the growth of the malignant mesothelioma market. This encompasses activities such as conducting scientific studies and running trials with the objective of formulating new medicinal drugs, treatments, and medical apparatus. The components of these activities involve assessing the safety, efficacy, and possible side effects of new products through painstakingly controlled clinical trials. These intensified efforts in clinical research and development are due to the escalating demand for novel and enhanced treatments, particularly in the face of an increase in chronic diseases and intricate conditions. The malignant mesothelioma market is propelled by these research and development efforts as they pace up progress in diagnostics, treatments, and targeted therapies while promoting groundbreaking approaches to improve early diagnosis, upgrade survival rates, and devise more effective, less invasive treatment alternatives. For example, Anadolu Agency, a Turkey-based state-run news entity, reported in January 2025 that clinical trials form almost 40% of the U.S. pharmaceutical research budget, which adds up to roughly $7 billion each year. Hence, the increasing research and development efforts are fuelling the growth of the malignant mesothelioma market.

Which Primary Segments of the Malignant Mesothelioma Market Are Driving Growth and Industry Transformations?

The malignant mesothelioma market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy

2) By Route Of Administration: Oral, Intravenous, Injectable, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies

4) By End-User: Hospitals, Oncology Clinics, Rehabilitation Centres, Research Laboratories

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy

3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery

4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy

5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22046&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Malignant Mesothelioma Market?# Market?

North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Malignant Mesothelioma Market?

Leading businesses in the malignant mesothelioma market are working on the creation of progressive treatment plans, such as the application of monoclonal antibody therapies, with the intention to suppress tumor progression and enhance the exactness of the treatment. To elaborate, monoclonal antibodies are fabricated proteins created in laboratories that can replicate the immune system’s detection and targeting capacities for specific antigens, like those on cancer cells. Take for example, Ono Pharmaceutical Co. Ltd, a prominent pharmaceutical firm from Japan, which in November 2023, won additional approval in Japan for the broadened use of Opdivo (nivolumab). Opdivo is a human anti-human PD-1 monoclonal antibody used for treating malignant mesothelioma, excluding malignant pleural mesothelioma. This fresh approval positions Opdivo as a novel treatment possibility for malignant mesothelioma in the absence of any established standard treatments. Furthermore, Opdivo was granted the status of an orphan drug for this specification, underlining its capacity to address major unmet medical needs.

View the full report here:

https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report

What Parameters Are Used to Define the Malignant Mesothelioma Market?

Malignant mesothelioma is a rare and aggressive type of cancer that primarily affects the mesothelium, a thin layer of tissue that covers most of the internal organs. It most commonly develops in the lining of the lungs (pleura) but can also occur in the lining of the abdomen (peritoneum), heart (pericardium), or testicles. The main risk factor for developing malignant mesothelioma is exposure to asbestos, a mineral once widely used in construction and manufacturing.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22046

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model